identifying the early warning signs of distressed ...©2013 gerbsman partners. all rights reserved....
TRANSCRIPT
©2013 Gerbsman Partners. All Rights Reserved.
Gerbsman Partners
Identifying the Early Warning Signs of Distressed Companies Strategies for Maximizing Value for Underperforming Loans & Grants
January 2013
Portfolio Advisory Services Assisting Investors and Lenders Identify the Early Warning Signs &
Maximizing Value of Distressed Portfolio Companies
July, 2014 ©2014 Gerbsman Partners. All Rights Reserved.
©2013 Gerbsman Partners. All Rights Reserved.
Strategic Advisory Services Overview
X
X
Discussion Topics
2
Diagnosing the Early Warning Signs of Distress
I
II
III Proprietary “Date Certain M&A Process”
©2013 Gerbsman Partners. All Rights Reserved.
Experience ● 32 years maximizing enterprise value for
highly-leveraged, underperforming, under valued, and under-capitalized companies and their intellectual property
● Crisis/Turnaround Management
● Portfolio Advisory
● Private Investment Banking
● Balance Sheet Restructuring
● IP Value Maximization
● Board of Intellectual Capital
Capabilities
Results
75 Life Science & Deals $ X
X X X
X X
$810M Value of terminated leases, sub-
debt and credit issues for companies
$2.3B Value of restructurings, M&A
and financing transactions
82 Technology, medical device, life
sciences, security, and solar portfolio companies assisted
Relationships ● Strong relationships with key stakeholders
including senior, subordinated and mezzanine debt lenders, venture capital firms and private equity investors.
Company Overview
4
©2013 Gerbsman Partners. All Rights Reserved.
Capability Snapshot
Gerbsman Partners’ Portfolio Advisory Service helps senior lenders and institutional investors uncover the early warning signs of distressed companies in their existing portfolios. We help our clients limit their downside risk by providing them with the information and strategies needed to intervene in advance of dissolution.
$ X
X X X
X X
Benefits
ü Detailed audit report identifying potential risks in investment and loan portfolios
ü Customized action plan to guide intervening parties
ü Maximize shareholder value and limit downside risk
Portfolio Advisory Service
5
Representative Clients
©2013 Gerbsman Partners. All Rights Reserved.
Process Overview
6
Phase I
Audit 2-3 day on sight visit by
Gerbsman Partners to perform audit and analysis of existing
portfolio companies
2-3 Days
Phase II
Review In person meetings with client to present findings, discuss risks and review recommendations
with management
1-2 Days
Phase III
Report Client receives written report highlighting underperforming
companies and recommendations for mitigating
losses 1 Day
©2013 Gerbsman Partners. All Rights Reserved.
Diagnosing the Early Warning Signs of Distress Section II
©2013 Gerbsman Partners. All Rights Reserved.
“Forget about profits, forget about the bottom line, forget about everything except CASH! There isn’t going to be any turnaround if there isn’t any cash.”
John O. Whitney (Inc. Magazine, March 1991)
Why Companies Fail
CA$H
Failure to Control
Failure to Preserve
Failure to Forecast
8
©2013 Gerbsman Partners. All Rights Reserved.
• Lack of leadership, motivation & management
• Broken or non-existent business model
• Malfeasance
• Technology failure
• Failure of board and/or lender oversight
• Uncontrolled growth
• Failure to respond to marketplace
• Diversification into non-core activities
• Failure to plan and budget
• Inadequate capital planning
• Excessive leverage
• Neglect of human resources
Other Explanations
9
Lack of accountability and responsibility by
management
©2013 Gerbsman Partners. All Rights Reserved.
Symptoms of Distress
Undercapitalization
Financial Performance
Operating Performance
Asset Utilization
10
©2013 Gerbsman Partners. All Rights Reserved.
Symptom 1 – Financial Performance
Sales
Profits
Profit Margins
Fixed Costs Debt Burden
Investors and lenders can start to identify trends on the income statement and balance sheet. The company starts missing sales goals, costs begin to rise and financial assumptions become invalid.
11
©2013 Gerbsman Partners. All Rights Reserved.
Symptom 2 – Asset Utilization
The company’s cash and working capital start deteriorating, they start paying their bills late, collections slow, loan balances begin to creep upward, and the company stops all unnecessary capital expenditures.
Cash
Working Capital
Quick Asset Ratio
Debt-to-Equity Ratio
Asset Turnover Rate
AR Rate
AR Aging
AP Aging
Capital Expenditures
12
©2013 Gerbsman Partners. All Rights Reserved.
Symptom 3 – Operating Performance
§ Missed projections
§ Market issues, gross margin, product positioning issues
§ Poor planning
§ Quality control problems
§ Late or slow delivery
§ Product unavailable
§ Management and personnel turnover
§ Lack of communication
§ Delay in preparing financial statements
§ Increasing stress felt by management
§ Failure of Board / Advisor oversight
§ Deliberate lack of transparency
§ Inability or unwillingness to explain financial situation simply & clearly
13
©2013 Gerbsman Partners. All Rights Reserved.
What Can You Do?
Expose management to crisis/turnaround management situations when symptoms start appearing and before
crisis situation exists.
Ask timely and direct questions to
key managers and employees
Hold company and management to
frequent reporting schedule. Make them
accountable and responsible for results.
Make management “Earn the Right” to
do business with lenders and investors
GOAL
14
©2013 Gerbsman Partners. All Rights Reserved.
Review of Business Model
15
Management & Board of Directors Review &Controls
Key Partnerships
Distribution Strategy
Product & Product Positioning
Architecture of a Sale
Gross Margin Analysis
Competition (Feature/Function/Benefit)
Market & Market Opportunity
©2013 Gerbsman Partners. All Rights Reserved.
Questions to Ask
Provide management, board, investors and lenders with information needed to determine what (if any) actions need to
be taken and how long the company can remain solvent
“Bottoms Up” Go Forward Cash Flow
16
Contingent Liabilities Liquidation Analysis
Accounts Receivable/Payables Aging Analysis
Status Update and Location of all IP and
Patents
Review of all Bank Covenants / Defaults
Board Member Involvement
Management Communications
Market, product, gross margin review
GOAL
©2013 Gerbsman Partners. All Rights Reserved.
Financial Tactics Emergency
Stage Stabilization
Stage Return to Growth
Stage Business Objective Manage for Immediate
Cash. Manage for Earnings. Manage for Future Growth.
Cash Flow Close the cash flow pipeline. Daily control to get positive flow.
Squeeze cash out of loose systems to become more liquid.
Redirect surplus to growth areas.
Profitability Not as important as cash flow. Achieved by divestment and drastic cost cutting.
Short-term ability becomes important. Achieve by running retained operations better.
Some trade-off versus short term against long term growth.
Balance Sheet Minimize debt service requirements and get bridge financing.
Restructure debt and get into short/long term balance.
Begin external financing.
Working Capital Squeeze cash and receivables, cut inventory, and collect payables.
Squeeze cash out of loose systems. Minimize float. Maintain tight discipline.
Capital Investment Curtail except in the core business.
Modest, constrained by internal sources.
Increase in strategic growth areas.
17
©2013 Gerbsman Partners. All Rights Reserved.
Partial Industry and Client Summary
18
Technology Software Emergent Game Technologies Capital Thinking Gentiae Inc. Metreo Inc. Neohapsis Inc Technion University Telecom Dialpad, Inc. Simpler Networks Storage Cornice Inc. PhaseMetrics Inc. Plasmon, Inc. Networking/Optical Networking Cambridge NanoTech, Inc. Transparent Networks, Inc Network Photonics, Inc. Mobile eBiz mobility YPS Software Teleflip
Medical Devices Cardiovascular, Vascular, Endoscopy Cardiomind inc. Myocor Inc NDO Surgical, Inc. XTENT Inc. Spine Applied Spine Technologies Inc . Respiratory Emphasis Medical Inc. Orthopeadics NovaLign Orthopedic Inc. Opthomology Optobionics - Retinal degeneration. Refractec, Inc Obesity Satiety Inc. - Obesity product
Media/Advertising/Internet Syncapse Active Response Group Inc. MeMedia Inc. Holographic & Biometric Technology Aprilis, Inc./Dow Corning Security NeoScale Inc. Oviso Inc. SciCortex, Inc.
Life Science Puristem, Inc Barnev Inc. Pegasus Biologics Inc Radiant Medical, Inc. Valentis, Inc.
Solar Nanosolar AQT Solar SVTC Solar
©2013 Gerbsman Partners. All Rights Reserved.
§ Stakeholders/shareholders made a strategic decision that access to future capital would be limited either by the initial investment group(s) or by market conditions
§ A decision was made or implied that existing management could not take the
company forward and/or there were major issues with the business model. § The company(s) typically had 0-6 months of CASH available § The Board of Directors and Shareholders wanted a "Clean" exit (no formal
bankruptcy, settlement of outstanding issues that demonstrate the Board is meeting/has met their fiduciary responsibilities, no potential lawsuits against" Deep Pocket" equity investors and a reduction of the significant time the Board and Shareholders were spending at/on the company)
§ Board of Directors wanted to maximize the value of the Intellectual Property
and other associated assets.
Typical Situation
©2013 Gerbsman Partners. All Rights Reserved.
Example: § Lack of hard assets § Intellectual property (e.g. patents, process) § Senior lender and/or other debt sources § Inexperienced entrepreneurs possibly with little or no operating
experience § No visibility to get to cash break-even in a reasonable timeframe § Unable to access debt or equity financing § The equity sponsor(s) has made the decision that they will no longer
fund the company
Maximizing Value of Intellectual Property
©2013 Gerbsman Partners. All Rights Reserved.
What is it worth? § "The Market" will determine the value. Who cares? § Customers, Competitors, Strategics and VC/Equity groups for portfolio
companies
Critical factors for success? § Domain expertise § Relevant IP/process § Resources and time available for date certain M&A process § Documented due diligence “war room” § Ownership and protection of IP/process
Maximizing Value of Intellectual Property
©2013 Gerbsman Partners. All Rights Reserved.
Action Plan Timeline
WEEK 0 1 2 3 4 5 6
STEP
S IN
TH
E P
RO
CESS
Bid Date
Package Business and IP
Summary
Create Due Diligence “War Room”
Populate “Deal Tracker”
Go-to-Market
Phase out use of IP
Identify and qualify prospects
Send out asset purchase agreement
Send deposit info
Bid Date
©2013 Gerbsman Partners. All Rights Reserved.
Contact Us
Gerbsman Partners
http://gerbsmanpartners.com [email protected]
http://blog.gerbsmanpartners.com 415-505-4991
24